126 related articles for article (PubMed ID: 38422618)
1. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract][Full Text] [Related]
2. Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.
Rolfo CD; Madison RW; Pasquina LW; Brown DW; Huang Y; Hughes JD; Graf RP; Oxnard GR; Husain H
Clin Cancer Res; 2024 Jun; 30(11):2452-2460. PubMed ID: 38526394
[TBL] [Abstract][Full Text] [Related]
3. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.
Li G; Pavlick D; Chung JH; Bauer T; Tan BA; Peguero J; Ward P; Kallab A; Bufill J; Hoffman A; Sadiq A; Edenfield J; He J; Cooke M; Hughes J; Forcier B; Nahas M; Stephens P; Ali SM; Schrock AB; Ross JS; Miller VA; Gregg JP
J Gastrointest Oncol; 2019 Oct; 10(5):831-840. PubMed ID: 31602320
[TBL] [Abstract][Full Text] [Related]
5. Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples.
Husain H; Pavlick DC; Fendler BJ; Madison RW; Decker B; Gjoerup O; Parachoniak CA; McLaughlin-Drubin M; Erlich RL; Schrock AB; Frampton GM; Das Thakur M; Oxnard GR; Tukachinsky H
JCO Precis Oncol; 2022 Oct; 6():e2200261. PubMed ID: 36265119
[TBL] [Abstract][Full Text] [Related]
6. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
7. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
Aldea M; Tagliamento M; Bayle A; Vasseur D; Vergé V; Marinello A; Danlos FX; Blanc-Durand F; Bernard E; Cerbone L; Mosele MF; Renneville A; Hadoux J; Loriot Y; Sakkal M; Vozy A; Sarkozy C; Smolenschi C; Nicotra C; Martin-Romano P; Boccon-Gibod C; Habza W; Lazarovici J; Ponce S; Hollebecque A; Marzac C; Lacroix L; Barlesi F; André F; Besse B; Rouleau E; Italiano A; Micol JB
JCO Precis Oncol; 2023 Mar; 7():e2200583. PubMed ID: 36862966
[TBL] [Abstract][Full Text] [Related]
8. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
[TBL] [Abstract][Full Text] [Related]
9. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53.
Wang Q; Dai HP; Liu DD; Xie JD; Yao H; Ding ZX; Tao TT; Chen SN; Zhang R
Leuk Res Rep; 2020; 14():100229. PubMed ID: 33194542
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
Kasi PM; Lee JK; Pasquina LW; Decker B; Vanden Borre P; Pavlick DC; Allen JM; Parachoniak C; Quintanilha JCF; Graf RP; Schrock AB; Oxnard GR; Lovly CM; Tukachinsky H; Subbiah V
Clin Cancer Res; 2024 Feb; 30(4):836-848. PubMed ID: 38060240
[TBL] [Abstract][Full Text] [Related]
12. Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing.
Hou Y; Zi J; Liu S; Ge Q; Ge Z
Mol Carcinog; 2023 Feb; 62(2):200-209. PubMed ID: 36300887
[TBL] [Abstract][Full Text] [Related]
13. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.
Stengel A; Baer C; Walter W; Meggendorfer M; Kern W; Haferlach T; Haferlach C
Blood Adv; 2021 Nov; 5(21):4426-4434. PubMed ID: 34570179
[TBL] [Abstract][Full Text] [Related]
14. Combined DNA Analysis from Stool and Blood Samples Improves Tumor Tracking and Assessment of Clonal Heterogeneity in Localized Rectal Cancer Patients.
Parigger T; Gassner FJ; Drothler S; Scherhäufl C; Hödlmoser A; Schultheis L; Bakar AA; Huemer F; Greil R; Geisberger R; Weiss L; Zaborsky N
Technol Cancer Res Treat; 2024; 23():15330338241252706. PubMed ID: 38766867
[No Abstract] [Full Text] [Related]
15. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
16. Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
Rosenthal SH; Gerasimova A; Ma C; Li HR; Grupe A; Chong H; Acab A; Smolgovsky A; Owen R; Elzinga C; Chen R; Sugganth D; Freitas T; Graham J; Champion K; Bhattacharya A; Racke F; Lacbawan F
PLoS One; 2021; 16(4):e0243683. PubMed ID: 33909614
[TBL] [Abstract][Full Text] [Related]
17. Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors.
Zollinger DR; Rivers E; Fine A; Huang Y; Son J; Kalyan A; Gray W; Baharian G; Hammond C; Ram R; Ringman L; Hafez D; Savel D; Patel V; Dantone M; Guo C; Childress M; Xu C; Johng D; Wallden B; Pokharel P; Camara W; Hegde PS; Hughes J; Carter C; Davarpanah N; Degaonkar V; Gupta P; Mariathasan S; Powles T; Ferree S; Dennis L; Young A
PLoS One; 2024; 19(5):e0302129. PubMed ID: 38753705
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors.
Zhou C; Yuan Z; Ma W; Qi L; Mahavongtrakul A; Li Y; Li H; Gong J; Fan RR; Li J; Molmen M; Clark TA; Pavlick D; Frampton GM; Forcier B; Moore EH; Shelton DK; Cooke M; Ali SM; Miller VA; Gregg JP; Stephens PJ; Li T
J Hematol Oncol; 2018 Nov; 11(1):129. PubMed ID: 30400986
[TBL] [Abstract][Full Text] [Related]
20. Defining the mutational profile of lower-risk myelodysplastic neoplasm patients with respect to disease progression using next-generation sequencing and pyrosequencing.
Adamska M; Kowal-Wiśniewska E; Czerwińska-Rybak J; Kiwerska K; Barańska M; Gronowska W; Loba J; Brzeźniakiewicz-Janus K; Wasilewska E; Łanocha A; Jarmuż-Szymczak M; Gil L
Contemp Oncol (Pozn); 2023; 27(4):269-279. PubMed ID: 38405213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
